Pulmonary diseases other than asthma as potential targets for antileukotriene therapy

Clinical Reviews in Allergy and Immunology

Volumn 17, Issue 1-2, 1999, Pages 247-260

  Peters Golden, Marc ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; COLCHICINE; DIETHYLCARBAMAZINE; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; PEPTIDOLEUKOTRIENE; PREDNISOLONE; ZILEUTON;

ADULT RESPIRATORY DISTRESS SYNDROME; ASBESTOSIS; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG DISEASE; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SARCOIDOSIS;

EID: 0032800008     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02737608     Document Type: Review

References (48)

1. Martin T, Raugi G, Merritt T, Henderson W Jr. Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage. J Clin Invest 1987;80:1114-1124.
2. Turnbull L, Turnbull L, Crofton J, Kay A. Variations in chemical mediators of hypersensitivity in the sputum of chronic bronchitics: Correlation with peak expiratory flow. Lancet 1978;2:184-186.
3. O'Driscoll B, Cromwell W, Kay A. Sputum leukotrienes in obstructive airways disease. Clin Exp Immunol 1984;55:397-404.
4. Zakrzewski J, Barnes N, Costello J, Piper P. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis 1987;136:779-782.
5. Piperno D, Pacheco Y, Hosni R, Moliere P, Gharib C, Lagarde M, Perrin-Fayolle M. Increased plasma levels of atrial natriuretic factor, renin activity, and leukotriene C4 in chronic obstructive pulmonary disease. Chest 1993;104:454-459.
6. Shindo K, Hirai Y, Fukumura M, Koide K. Plasma levels of leukotriene E4 during clinical course of chronic obstructive pulmonary disease. Prostaglandins 1997;56:213-217.
7. Ozaki O, Hayashi H, Tani K, Ogushi F, Yasuoka U, Ogura T. Neutrophil chemotactic factor in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992;145:85-91.
8. Konstan M, Walenga R, Hilliard K, Hilliard J. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993;148:896-901.
9. Sampson A, Spencer D, Green C, Piper P, Price J. Leukotrienes in the sputum and urine of cystic fibrosis children. Brit J Clin Pharmacol 1990;30:861-869.
10. Greally P, Hussein M, Cook A, Sampson A, Piper P, Price JF. Sputum tumour necrosis factora and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993;68:389-392.
11. Spencer D, Sampson A, Green C, Costello J, Piper P, Price J. Sputum cysteinyl-leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 1992;12:90-94.
12. Greally P, Cook A, Sampson A, Coleman R, Chambers S, Piper P, Price J. Atopic children with cystic fibrosis have increased urinary leukotriene E4 concentrations and more severe pulmonary disease. J Allergy Clin Immunol 1994;93:100-107.
13. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: Evidence of a pathogenetic role for leukotriene B4. Lancet 1993;342:465-469.
14. Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid with diffuse panbronchiolitis. Chest 1995;108:115-122.
15. Seeger W, Grimminger F, Barden M, Becker G, Lohmeyer J, Heinrich D, Lasch H. Omega-oxidized leukotriene B4 deteced in the broncho-alveolar lavage fluid of patients with noncardiogenic pulmonary edema, but not in those with cardiogenic edema. Intensive Care Med 1991;17:1-6.
16. Antonelli M, Raponi G, Lenti L, Severi L, Capelli O, Riccioni L, De Blasi R, Conti G, Mancini C. Leukotrienes and alpha tumor necrosis factor levels in the bronchoalveolar lavage fluid of patient at risk for the adulr respiratory distress syndrome. Minerva Anestesiol 1994;60:419-426.
17. Antonelli M, Bufi M, De Blasi R, Crim G, Conti G, Mattia C, Vivino G, Lenti L, Lombardi D, Dotta A, Pontieri G, Gasparetto A. Detection of leukotrienes B4, C4 and of their isomers in arterial, mixed venous blood and bronchoalveolar lavage fluid from ARDS patients. Intensive Care Med 1989;15:296-301.
18. Stephenson A, Lonigro A, Hyers T, Webster R, Fowler A. Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk of ARDS. Am Rev Respir Dis 1988;138:714-719.
19. Matthay M, Eschenbacher W, Goetzl E. Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome. J Clin Immunol 1984;4:479-483.
20. Schonfeld W, Knoller J, Joka T, Obertacke U, Konig W. Leukotriene generation in patients with multiple injuries. J Trauma 1992;33:799-806.
21. Fauler J, Tsikas D, Holch M, Seekamp A, Nerlich M, Sturm J, Frolich J. Enhanced urinary excretion of leukotriene E4 by patients with multiple trauma with or without adult respiratory distress syndrome. Clin Sci 1991;80:497-504.
22. Bernard G, Korley V, Swindell B, Ford-Hutchinson A, Tagari P. Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1991;144:263-267.
23. Burghardt J, Boros V, Biggs D, Olson D. Lipid mediators in oxygen-induced airway remodeling and hypertension in newborn rats. Am J Respir Crit Care Med 1996;154:837-842.
24. Taniguchi H, Taki F, Takagi K, Satake T, Sugiyama S, Ozawa T. The role of leukotriene B4 in the genesis of oxygen toxicity in the lung. Am Rev Respir Dis 1986;133:805-808.
25. Coggeshall J, Christman B, Lefferts P, Serafin W, Blair I, Butterfield M, Snapper J. Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep. J Appl Physiol 1998;65:1351-1359.
26. Fink M, O'Sullivan B, Menconi M, Wollert P, Wang H, Youssef M, Fleisch J. A novel leukotriene B4-receptor antagonist in endotoxin shock: A prospective, controlled trial in a porcine model. Crit Care Med 1993;21:1825-1837.
27. Wollert P, Menconi M, O'Sullivan B, Wang H, Larkin V, Fink M. LY255283, a Novel Leukotriene B4 Receptor Antagonist, Limits Activation of Neutrophils and Prevents Acute Lung Injury Induced by Endotoxin in Pigs. 1993;114:191-198.
28. VanderMeer T, Menconi M, O'Sullivan B, Larkin V, Wang H, Sofia M, Fink M. Acute lung injury in endotoxemic pigs role of leukotriene B4. J Appl Physiol 1995;78:1121-1131.
29. 4 antagonist, on pulmonary function and mesenteric perfusion in a porcine model of endotoxic shock and ARDS. Circ Shock 1991;33:7-16.
30. Wardlaw A, Hay H, Cromwell O, Collins J, Kay A. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989;84:19-26.
31. Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996;97:1827-1836.
32. Garcia J, Griffith D, Cohen A, Callahan K. Alveolar macrophages from patients with asbestos exposure release increased levels of leuLotriene B4. Am Rev Respir Dis 1989;139:1494-1501.
33. De Rose V, Trentin L, Crivellari M, Cipriani A, Gialdroni G G, Pozzi E, Folco G, Semenzato G. Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis. Thorax 1997;52:76-83.
34. Bachwich P, Lynch J III, Kunkel S. Arachidonic acid metabolism is altered in sarcoid alveolar macrophages. Clin Immunol Immunopathol 1987;42:27-37.
35. Hackshaw K, Voelkel N, Thomas R, Westcott J. Urine leukotriene E4 levels are elevated in patients with active systemic lupus erythematosus. J Rheumatol 1992;19:252-258.
36. Hackshaw K, Shi Y, Brandwein S, Jones K, Westcott J. A pilot study of zileuton, a selective 5-lipoxygenase inhibitor in systemic lupus erythematosis. J Rheumatol 1995;22:462-468.
37. Douglas W, Ryu J, Bjoraker J, Schroeder D, Myers J, Tazelaar H, Swensen S, Scanlon P, Peters S, DeRemee R. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997;72:201-209.
38. Peters-Golden M, McNish R, Davis J, Blackwood R, Brock T. Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. Am J Physiol (Lung Cell Mol Physiol) 1996;271:L1004-L1013.
39. Phan S, Kunkel S. Inhibition of bleomycin-induced pulmonary fibrosis by nordihydroguiarctic acid. The role of alveolar macrophage activation and mediator production. Am J Pathol 1986;124:343-352.
40. Ziboh V, Yun M, Hyde D, Giri S. Gamma-linolenic acid-containing diet attenuates bleomycin-induced lung fibrosis in hamsters. Lipids 1997;32:759-767.
41. Stenmark K, James S, Voelkel N, Toews W, Reeves J, Murphy R. Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. New Engl J Med 1983;309:77-80.
42. Morganroth M, Stenmark K, Morris K, Murphy R, Mathias M, Reeves J, Voelkel N. Diethylcarbamazine inhibits acute and chronic hypoxic pulmonary hypertension in awake rats. Am Rev Respir Dis 1985;131:488-492.
43. Voelkel N, Tuder R, Wade K, Hoper M, Lepley R, Goulet J, Koller B, Fitzpatrick F. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypetension in hypoxic rats. J Clin Invest 1996;97:2491-2498.
44. Tabata T, Ono S, Song C, Noda M, Suzuki S, Tanita T, Fujimura S. Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension. Jap J Thorac Dis 1997;35:160-166.
45. Li J, Oliver J, Lu C, Phillips J. Delayed thromboxane or tumor necrosis factor-alpha, but not leukotriene inhibition, attenuates prolonged pulmonary hypertension in endotoxemia. Am J Med Sci 1995;310:103-110.
46. Smalley W, DuBois R. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20.
47. Avis I, Jett M, Boyle T, Vos M, Mood T, Treston A, Martinez A, Muslhine J. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996;97:806-813.
48. Vincent J, Vermeer M, Kort W, Zijlstra F. The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat. Biochim Biophys Acta 1990;1042:255-258.